← Eichor
Condition: Cholangiocarcinoma Non Resectable Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cholangiocarcinoma Non Resectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C
NA · 8 location(s) · Aichi Medical University · NCT07235007A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2 · 44 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05678270Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06298968TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepati
Phase 2 · 7 location(s) · University Hospital, Montpellier · NCT03364530Liver Transplantation in Intrahepatic Cholangiocarcinoma
Phase N/A · 2 location(s) · Rutgers, The State University of New Jersey · NCT06140134Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT05342194LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
NA · 1 location(s) · Azienda Sanitaria Ospedaliera · NCT06125769Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06986486Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangioca
Phase 2 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT04891289Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
NA · 8 location(s) · Erasmus Medical Center · NCT06493734Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based o
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06849180Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Phase 2 · 10 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06440993A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06925516Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06862934Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unr
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06852287Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta
Phase 1/Phase 2 · 38 location(s) · Institut de Recherches Internationales Servier · NCT06501625Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
NA · 1 location(s) · Azienda Sanitaria Ospedaliera · NCT06098547Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcin
Phase N/A · 1 location(s) · Hospital Vall d'Hebron · NCT04378023Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2 · 1 location(s) · Tongji Hospital · NCT06192797A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cis
Phase 1/Phase 2 · 1 location(s) · Shanghai 6th People's Hospital · NCT07632235CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Phase N/A · 1 location(s) · Fujian Provincial Hospital · NCT06643208High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05053555PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05286814Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Phase 4 · 20 location(s) · University of Leipzig · NCT05551299Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Chola
Phase 2 · 1 location(s) · Jinbo Yue · NCT07030140Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Phase 2 · 4 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06274879Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641036
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.